---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-23-007815"
form_type: "8-K"
ticker: "PHIO"
cik: "0001533040"
company_name: "Phio Pharmaceuticals Corp."
filed_at: "2023-11-09T23:59:59+00:00"
generated_at: "2026-06-08T06:39:39.670330+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Phio Pharma Q3 net loss narrows to $2.8M; first patient dosed in PH-762 Phase 1b trial

## Summary
- Q3 net loss $2.8M ($1.14/sh) vs $3.6M ($3.14/sh) in Q3 2022; cash at Sep 30 $8.4M down from $11.8M at Dec 31 2022.
- R&D expenses fell 28% YoY to $1.8M; G&A fell 9% to $1.0M.
- First patient dosed in U.S. Phase 1b trial of intratumoral PH-762 (anti-PD-1) for skin carcinomas (NCT06014086).
- Trial expected to enroll up to 30 patients across 4-6 U.S. sites; neoadjuvant monotherapy with dose escalation.
- Company presented preclinical data on PH-894 (BRD4) and CTLA-4-targeting INTASYL at recent conferences.

## SEC filing metadata
- accession: 0001683168-23-007815
- form_type: 8-K
- ticker: PHIO
- cik: 0001533040
- company_name: Phio Pharmaceuticals Corp.
- filed_at: 2023-11-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1533040/000168316823007815/0001683168-23-007815-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1533040/000168316823007815/phio_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-23-007815
- JSON: https://secwatch.observer/filing/0001683168-23-007815.json
- Plain text: https://secwatch.observer/filing/0001683168-23-007815.txt

## Key facts
- Earnings Releases
  Phio Pharmaceuticals Corp. reported the quarter ended September 30, 2023 results: net income Net loss was $2.8 million, or $1.14 per share.
  - Period: the quarter ended September 30, 2023
  - Net income: Net loss was $2.8 million, or $1.14 per share
  - Result: reported results
  source text: Phio Pharmaceuticals Corp. (the “Company”) reported its financial results for the period ended September 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1533040/000168316823007815/0001683168-23-007815-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.